Cargando…

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study

SUMMARY: The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate. It provided a new choice for osteoporosis treatment in Chinese population. INTRODUCTION: To determine whether the efficacy of generic teriparatide is nonin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Mei, Zhang, Zhenlin, Xue, Qingyun, Li, Qifu, Jin, Xiaolan, Dong, Jin, Cheng, Qun, You, Li, Lin, Hua, Tang, Hai, Shen, Lin, Gao, Xin, Hu, Ji, Chao, Aijun, Li, Pengqiu, Shi, Rui, Zheng, Shuhui, Zhang, Ying, Xiong, Xiaojiang, Yu, Wei, Xia, Weibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334369/ https://www.ncbi.nlm.nih.gov/pubmed/35900607 http://dx.doi.org/10.1007/s11657-022-01131-8

Ejemplares similares

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment
por: Nayak, Smita, et al.
Publicado: (2012)

An effect comparison of alendronate and teriparatide in patients with glucocorticoid-induced osteoporosis: A protocol for systematic review and meta-analysis
por: Liang, Na, et al.
Publicado: (2022)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
por: Taheri, Saeed, et al.
Publicado: (2019)

Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
por: Panico, Annalisa, et al.
Publicado: (2011)

Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study
por: Yang, Dazhi, et al.
Publicado: (2023)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials
por: Liu, Zhi-Ming, et al.
Publicado: (2022)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Vertebral Collapse Prevented Following Teriparatide Treatment in Postmenopausal Kümmell's Disease Patients with Severe Osteoporosis
por: Gou, Peng‐guo, et al.
Publicado: (2021)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study
por: Yang, Tiansong, et al.
Publicado: (2019)

Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters
por: Sandeep, Nandipati Venkata, et al.
Publicado: (2022)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
por: Chen, Ling-Xiao, et al.
Publicado: (2015)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax(®)) for osteoporosis treatment
por: Unnanuntana, Aasis, et al.
Publicado: (2017)

The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis
por: Ouyang, YuLong, et al.
Publicado: (2021)

Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density
por: Yuan, Hu, et al.
Publicado: (2023)

Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study
por: Grima, Daniel T, et al.
Publicado: (2010)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
por: Ljunggren, Östen, et al.
Publicado: (2013)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_am61lpg2leruarb7a6bn63o39c